安罗替尼联合信迪利单抗治疗中晚期肝细胞癌的疗效和安全性:单中心回顾性真实世界研究OA
Efficacy and safety of anlotinib combined with sintilimab in patients with intermediate-to-advanced hepatocellular carcinoma:a single-center retrospective real-world study
目的 探讨真实世界中安罗替尼联合信迪利单抗治疗中晚期肝细胞癌的疗效和安全性.方法 回顾性分析2022年1月至2024年12月在广西壮族自治区民族医院接受至少2个周期安罗替尼联合信迪利单抗治疗的40例中晚期肝细胞癌患者资料,根据是否联合经导管动脉化疗栓塞术(TACE)进行探索性分组比较.采用改良实体瘤疗效评价标准(mRECIST)评价肿瘤疗效,分析客观缓解率(ORR)、疾病控制率(DCR)、无进展生存期(PFS)、总生存期(OS)及治疗相关不良事件.随访截止日期为2024年12月31日.结果 40例患者的DCR为85.00%(34/40),ORR为22.50%(9/40).联合TACE组与未联合TACE组DCR分别为95.24%和73.68%,ORR分别为33.33%和10.53%,差异均无统计学意义(P=0.085、0.133).两组中位PFS分别为11.86个月和9.58个月,中位OS分别为23.54个月和15.90个月,差异均无统计学意义(P=0.534、0.205).调整巴塞罗那临床肝癌(BCLC)分期和甲胎蛋白(AFP)水平后,联合TACE与PFS及OS均未见独立相关性(均P>0.05).AFP<400 ng/mL组OS长于AFP≥400 ng/mL组(P=0.017),两组PFS差异无统计学意义(P=0.078).33例患者发生至少1项治疗相关不良事件,其中9例发生≥3级不良事件,包括1例4级血小板计数降低;未发生5级不良事件.结论 在完成至少2个治疗周期的中晚期肝细胞癌患者中,安罗替尼联合信迪利单抗显示出一定的抗肿瘤活性,安全性总体可管理.联合TACE组疗效指标和生存时间在数值上较高,但未达到统计学显著性,相关结果仍需大样本前瞻性研究验证.
Objective To evaluate the real-world efficacy and safety of anlotinib combined with sintilimab in patients with intermediate-to-advanced hepatocellular carcinoma(HCC).Methods This retrospective study included 40 patients with intermediate-to-advanced HCC who received at least two cycles of anlotinib combined with sintilimab between January 2022 and December 2024.Exploratory comparisons were performed according to whether patients additionally received transarterial chemoembolization(TACE).Tumor response was evaluated according to the modified Response Evaluation Criteria in Solid Tumors(mRECIST).Objective response rate(ORR),disease control rate(DCR),progression-free survival(PFS),overall survival(OS),and treatment-related adverse events were analyzed.Follow-up ended on December 31,2024.Results The overall DCR and ORR were 85.00%(34/40)and 22.50%(9/40),respectively.The DCRs in the TACE and non-TACE groups were 95.24%and 73.68%,and the corresponding ORRs were 33.33%and 10.53%;neither difference was statistically significant(P=0.085 and 0.133,respectively).Median PFS was 11.86 months in the TACE group and 9.58 months in the non-TACE group,while median OS was 23.54 and 15.90 months,respectively;neither difference was statistically significant(P=0.534 and 0.205,respectively).After adjustment for Barcelona Clinic Liver Cancer stage and alpha-fetoprotein(AFP)level,additional TACE was not independently associated with PFS or OS(both P>0.05).Patients with AFP levels<400 ng/mL had longer OS than those with AFP levels≥400 ng/mL(P=0.017),whereas PFS did not differ significantly between the two AFP groups(P=0.078).Treatment-related adverse events occurred in 33 patients,and nine patients experienced grade≥3 events,including one case of grade 4 decreased platelet count.No grade 5 events occurred.Conclusion Among patients who completed at least two treatment cycles,anlotinib combined with sintilimab showed potential antitumor activity and generally manageable safety.Although response rates and survival times were numerically higher in the TACE group,the differences were not statistically significant.These findings require confirmation in larger prospective studies.
罗秀;农先胜;杨小叶;黄美虹;吕聪;陆海鹏
广西壮族自治区民族医院药学部,南宁 530001广西壮族自治区民族医院肿瘤科,南宁 530001广西壮族自治区民族医院药学部,南宁 530001广西壮族自治区民族医院药学部,南宁 530001广西壮族自治区民族医院药学部,南宁 530001广西壮族自治区民族医院药学部,南宁 530001
安罗替尼信迪利单抗中晚期肝细胞癌疗效安全性
anlotinibsintilimabintermediate-to-advanced hepatocellular carcinomaefficacysafety
《中华灾害救援医学》 2026 (8)
879-884,6
广西壮族自治区科技计划项目(Z-F20231700)
评论